Literature DB >> 8773300

Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic.

W G Stetler-Stevenson1, R Hewitt, M Corcoran.   

Abstract

Tumor cell invasion is now viewed as dysregulated physiologic invasion. Investigators have started to define the molecular events that are involved in this process. We find that there are many functional similarities with molecular events involved in physiologic process such as angiogenesis and wound healing. Matrix metalloproteinase activity is a common denominator in these pathologic conditions and in normal responses. Studies using endogenous metalloproteinase inhibitors suggest that targeting matrix metalloproteinase activity may prevent tumor cell dissemination. The development and pre-clinical testing of novel, low molecular weight matrix metalloproteinase inhibitors support this concept and suggest that an exciting new era of cancer therapy is on the horizon.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8773300     DOI: 10.1006/scbi.1996.0020

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  70 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 2.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 3.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

4.  Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.

Authors:  Jingquan Jia; Andrew E Dellinger; Eric S Weiss; Anuradha Bulusu; Christel Rushing; Haiyan Li; Leigh A Howard; Neal Kaplan; Herbert Pang; Herbert I Hurwitz; Andrew B Nixon
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

5.  Conformational variability of matrix metalloproteinases: beyond a single 3D structure.

Authors:  Ivano Bertini; Vito Calderone; Marta Cosenza; Marco Fragai; Yong-Min Lee; Claudio Luchinat; Stefano Mangani; Beatrice Terni; Paola Turano
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

6.  Sulforaphane as a Promising Natural Molecule for Cancer Prevention and Treatment.

Authors:  Osama A Elkashty; Simon D Tran
Journal:  Curr Med Sci       Date:  2021-04-20

7.  Effects of fibril- or fixed-collagen on matrix metalloproteinase-1 and tissue inhibitor of matrix metalloproteinase-1 production in the human hepatocyte cell line HLE.

Authors:  Makoto Nakamuta; Kazuhiro Kotoh; Munechika Enjoji; Hajime Nawata
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

8.  Proteolytic activity of human non-Hodgkin's lymphomas.

Authors:  A E Kossakowska; A Hinek; D R Edwards; M S Lim; C L Zhang; D R Breitman; C Prusinkiewicz; A L Stabbler; L S Urbanski; S J Urbanski
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

9.  Front instabilities and invasiveness of simulated avascular tumors.

Authors:  Nikodem J Popławski; Ubirajara Agero; J Scott Gens; Maciej Swat; James A Glazier; Alexander R A Anderson
Journal:  Bull Math Biol       Date:  2009-02-21       Impact factor: 1.758

10.  Inhibitory effect of Aspergillus fumigatus extract on matrix metalloproteinases expression.

Authors:  Farshid Saadat; Kamiar Zomorodian; Mohammad Pezeshki; Sassan Rezaie; Mohammad Reza Khorramizadeh
Journal:  Mycopathologia       Date:  2004-07       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.